NYMOX REPORTS PROSTATIC HYPERPLASIA TRIAL DATA

Nymox Pharmaceutical has announced that interim safety analysis of its ongoing multicenter Phase II trial of NX-1207 has revealed no serious drug side effects.

NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH) which the company believes shows good promise as a potential first-line treatment for BPH. In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant side effects. The Phase II trial is expected to be completed later this year.

In the Phase I-II trials to date, the subjects treated with NX-1207 showed a statistically significant overall mean symptom improvement of 6.87 points (compared to 0.5 for controls) and a statistically significant shrinkage in prostate size. There were no significant adverse side effects from the drug in these trials. Significantly, subjects followed for up to two years post-treatment showed even further statistically significant symptom improvement of 9.3 points.